All Controlled release and advanced delivery articles
-
NewsChiesi and Bespak further collaboration to advance UK production of low carbon inhalers
Partnership increases industrial scale of low carbon pressurised metered dose inhalers (pMDIs), accelerating pharma’s transition to a more sustainable option.
-
NewsNanoparticle–ultrasound combo could boost drug release in bacterial biofilms
Study findings offer potential to improve drug efficacy of hard-to-deliver antibiotics.
-
NewsLipid nanoparticle discovery could increase drug delivery efficiency
Study findings offer potential to accelerate development of RNA-based medicines.
-
NewsTeva’s migraine biologic Ajovy marks phase III progress for paediatric patients
The monoclonal antibody could provide a new preventative treatment option for episodic migraines, new late-stage data suggests.
-
NewsPolymer capsule drug delivery innovation demonstrates sustainability promise
Synthesis of the naturally-derived capsules provide a sustainable alternative to traditional, microplastic-contributing drug delivery options.
-
WebinarPractical considerations for aseptic gowning in contamination control strategies
Watch this webinar as we examine the main personnel-related factors that could lead to particle/microbial contamination risks of the product and outline practical measures that can mitigate these risks.
-
NewsNanexa collaboration to enhance Moderna’s mRNA drug delivery
Moderna’s $500 million deal with Nanexa will focus on improving long-acting injectable drug delivery, potentially improving mRNA medicines.
-
-
News
Chiesi gains pace on climate target with new carbon minimal inhaler data
Findings presented at the British Thoracic Society (BTS) Winter Meeting back biopharma’s Net Zero commitment.
-
NewsChiesi completes expansion of French metered dose inhaler facility
The enlarged La Chaussée-Saint-Victor site will serve as a manufacturing hub for the biopharma company.
-
NewsSirolimus-eluting balloon offers potential “paradigm shift” in restenosis treatment
Treatment provided a promising alternative to standard care in repeat percutaneous coronary interventions in the first-of-a-kind trial.
-
NewsPhase III data for next-gen green inhaler push GSK closer to Net Zero targets
New findings support use of salbutamol MDI formulation in the next-generation low carbon propellant as a more sustainable option for patients with respiratory disease.
-
WebinarAutomating quality control testing for radiopharmaceutical production
This webinar showcased a rapid microbial method that can help to address the time to result challenge posed by short shelf-life radiopharmaceuticals.
-
NewsCPHI Pharma Awards 2025 finalists announced
Winners of this year's awards will be revealed during the opening of CPHI Frankfurt 2025.
-
NewsFDA approves first-of-a-kind intravesical drug delivery system for bladder cancer
The innovation is set to change how eligible bladder cancer patients in the US are treated who are unresponsive to traditional therapy.
-
NewsRoche en route to first continuous delivery treatment for nAMD in Europe
CE mark for Contivue platform supports its ambitions for Susvimo in age-related macular degeneration (AMD).
-
NewsUnderstanding European regulatory requirements for low-GWP propellant transition
The paper explores recent guidance by the EMA and aims to help companies ensure their developments are efficient and effective for the forthcoming transition.
-
NewsNanoscope gene therapy data signals potential retinal disease advancement
Further to its potential in Stargardt disease, if approved, the one-time gene therapy could become standard of care for retinitis pigmentosa, alongside other retinal degenerative diseases.
-
ArticleScaling for the GLP-1 revolution - meeting global injectable demand
In this article, Miguel Angel Ortega Sánchez of ROIS explores how the industry is adapting to new delivery formats, device bottlenecks, and strategic partnership models — and why flexibility, compliance, and tech transfer agility are now critical to success.
-
WebinarThe future of contamination control in pharma: from compliance to innovation
This webinar explores the benefits of accelerated microbial identification using MALDI-TOF in pharmaceutical contamination control strategies.